After-Hours Movers 10/31: (NBIX) (LEAP) (WINN) Higher; (EXEL) (BGC) (CAVM) (ROG) Lower
Tweet
Share
E-mail
Get Alerts EXEL Hot Sheet
Up)Join SI Premium – FREE
Exelixis (Nasdaq: EXEL) 35% LOWER; announced it will initiate the first Phase 3 '306 pivotal trial of cabozantinib in patients with metastatic CRPC. Pain will be the primary efficacy endpoint for the trial. The company was not able to reach a timely agreement with the FDA under a SPA on the proposed design and analysis of the '306 trial. Exelixis expects to begin the '307 pivotal trial during the first half of next year.
General Cable Corp. (NYSE: BGC) 12.4% LOWER; reported Q3 EPS of $0.33, vs. the analyst estimate of $0.72. Revenue for the quarter came in at $1.52 billion versus the consensus estimate of $1.61 billion. Sees Q4 2011 revenue of $1.4-$1.45 billion, versus the consensus of $1.56 billion.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) 12% HIGHER; reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.
Leap Wireless International, Inc. (NASDAQ: LEAP) 9.5% HIGHER; reported Q3 loss of $0.90, versus the analyst estimate of ($0.79). Revenue for the quarter came in at $76.3 million versus the consensus estimate of $763.63 million.
CAVIUM (NASDAQ: CAVM) 9.5% LOWER; reported Q3 EPS of $0.27, $0.01 better than the analyst estimate of $0.26. Revenue for the quarter came in at $67.7 million versus the consensus estimate of $68.19 million. On its conference call, said it expects adj-EPS of 19-20 cents, vs. the consensus of 26 cents.
Winn-Dixie Stores, Inc. (NASDAQ: WINN) 8.4% HIGHER; reported Q1 EPS of ($0.44), $0.02 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.6 billion.
Rogers Corp. (NYSE: ROG) 7% LOWER; reported Q3 EPS of $0.81, $0.02 better than the analyst estimate of $0.79. Revenue for the quarter came in at $147.6 million versus the consensus estimate of $148.35 million.
Avalonbay Communities, Inc. (NYSE: AVB) 5% LOWER; reported Q3 FFO of $1.17, $0.02 worse than the analyst estimate of $1.19. Sees Q4 FFO of $1.19-$1.23, vs. the consensus of $1.27. Cuts its FY11 FFO guidance from $4.60-$4.75 to $4.57-$4.61, vs. the consensus of $4.66.
PURE Bioscience, Inc. (NASDAQ: PURE) 4.3% LOWER; reported Q4 EPS of ($0.05), versus ($0.05) reported last year. Revenue for the quarter came in at $244 thousand, versus $324 thousand reported last year.
Skilled Healthcare Group (NYSE: SKH) 3.8% HIGHER; reported Q3 EPS of $0.32, $0.02 better than the analyst estimate of $0.30. Revenue for the quarter came in at $217.2 million versus the consensus estimate of $218.17 million.
Herbalife (NYSE: HLF) 3.6% LOWER; reported Q3 EPS of $0.87, $0.11 better than the analyst estimate of $0.76. Revenue for the quarter came in at $895.22 million versus the consensus estimate of $845.2 million. Herbalife sees Q4 2011 EPS of $0.68-$0.72, versus the consensus of $0.74. Herbalife sees FY2012 EPS of $3.25-$3.45, versus the consensus of $3.57. Sees sales up 8-10 percent compared to 2011.
Allstate Corp. (NYSE: ALL) 3.4% HIGHER; reported Q3 EPS of $0.16, $0.08 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $8.24 million versus the consensus estimate of $6.74 billion.
AsiaInfo-Linkage, Inc. (NASDAQ: ASIA) 1.2% HIGHER; reported Q3 EPS of $0.37, ex-items, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $117.2 million versus the consensus estimate of $117.08 million. Sees Q4 2011 revenue of $127-$131 million, versus the consensus of $129.43 million.
Array Biopharma, Inc. (NASDAQ: ARRY) 1.2% LOWER; reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Anadarko Petroleum Corp. (NYSE: APC) 1% HIGHER; reported Q3 EPS of $0.66, $0.10 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $3.2 billion versus the consensus estimate of $3.39 billion. The GAAP loss was $6.12 per share.
General Cable Corp. (NYSE: BGC) 12.4% LOWER; reported Q3 EPS of $0.33, vs. the analyst estimate of $0.72. Revenue for the quarter came in at $1.52 billion versus the consensus estimate of $1.61 billion. Sees Q4 2011 revenue of $1.4-$1.45 billion, versus the consensus of $1.56 billion.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) 12% HIGHER; reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.
Leap Wireless International, Inc. (NASDAQ: LEAP) 9.5% HIGHER; reported Q3 loss of $0.90, versus the analyst estimate of ($0.79). Revenue for the quarter came in at $76.3 million versus the consensus estimate of $763.63 million.
CAVIUM (NASDAQ: CAVM) 9.5% LOWER; reported Q3 EPS of $0.27, $0.01 better than the analyst estimate of $0.26. Revenue for the quarter came in at $67.7 million versus the consensus estimate of $68.19 million. On its conference call, said it expects adj-EPS of 19-20 cents, vs. the consensus of 26 cents.
Winn-Dixie Stores, Inc. (NASDAQ: WINN) 8.4% HIGHER; reported Q1 EPS of ($0.44), $0.02 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.59 billion versus the consensus estimate of $1.6 billion.
Rogers Corp. (NYSE: ROG) 7% LOWER; reported Q3 EPS of $0.81, $0.02 better than the analyst estimate of $0.79. Revenue for the quarter came in at $147.6 million versus the consensus estimate of $148.35 million.
Avalonbay Communities, Inc. (NYSE: AVB) 5% LOWER; reported Q3 FFO of $1.17, $0.02 worse than the analyst estimate of $1.19. Sees Q4 FFO of $1.19-$1.23, vs. the consensus of $1.27. Cuts its FY11 FFO guidance from $4.60-$4.75 to $4.57-$4.61, vs. the consensus of $4.66.
PURE Bioscience, Inc. (NASDAQ: PURE) 4.3% LOWER; reported Q4 EPS of ($0.05), versus ($0.05) reported last year. Revenue for the quarter came in at $244 thousand, versus $324 thousand reported last year.
Skilled Healthcare Group (NYSE: SKH) 3.8% HIGHER; reported Q3 EPS of $0.32, $0.02 better than the analyst estimate of $0.30. Revenue for the quarter came in at $217.2 million versus the consensus estimate of $218.17 million.
Herbalife (NYSE: HLF) 3.6% LOWER; reported Q3 EPS of $0.87, $0.11 better than the analyst estimate of $0.76. Revenue for the quarter came in at $895.22 million versus the consensus estimate of $845.2 million. Herbalife sees Q4 2011 EPS of $0.68-$0.72, versus the consensus of $0.74. Herbalife sees FY2012 EPS of $3.25-$3.45, versus the consensus of $3.57. Sees sales up 8-10 percent compared to 2011.
Allstate Corp. (NYSE: ALL) 3.4% HIGHER; reported Q3 EPS of $0.16, $0.08 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $8.24 million versus the consensus estimate of $6.74 billion.
AsiaInfo-Linkage, Inc. (NASDAQ: ASIA) 1.2% HIGHER; reported Q3 EPS of $0.37, ex-items, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $117.2 million versus the consensus estimate of $117.08 million. Sees Q4 2011 revenue of $127-$131 million, versus the consensus of $129.43 million.
Array Biopharma, Inc. (NASDAQ: ARRY) 1.2% LOWER; reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Anadarko Petroleum Corp. (NYSE: APC) 1% HIGHER; reported Q3 EPS of $0.66, $0.10 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $3.2 billion versus the consensus estimate of $3.39 billion. The GAAP loss was $6.12 per share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- Inflation relief has likely been delayed not destroyed - GS
- This is how much FTSE 100 and FTSE 250 are likely to gain in 2024 - UBS
Create E-mail Alert Related Categories
Special ReportsRelated Entities
After-Hours MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
